MX2024011346A - Compuestos inhibidores de la interaccion proteina-proteina de mll1-wdr5 de cruce de la barrera hematoencefalica y usos de estos - Google Patents

Compuestos inhibidores de la interaccion proteina-proteina de mll1-wdr5 de cruce de la barrera hematoencefalica y usos de estos

Info

Publication number
MX2024011346A
MX2024011346A MX2024011346A MX2024011346A MX2024011346A MX 2024011346 A MX2024011346 A MX 2024011346A MX 2024011346 A MX2024011346 A MX 2024011346A MX 2024011346 A MX2024011346 A MX 2024011346A MX 2024011346 A MX2024011346 A MX 2024011346A
Authority
MX
Mexico
Prior art keywords
protein
mll1
blood
brain barrier
inhibitor compounds
Prior art date
Application number
MX2024011346A
Other languages
English (en)
Spanish (es)
Inventor
Farbod Shojaei
Che Fang
J Edward Semple
Mireille Gillings
Original Assignee
Huyabio Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc filed Critical Huyabio Int Llc
Publication of MX2024011346A publication Critical patent/MX2024011346A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024011346A 2022-03-14 2024-09-13 Compuestos inhibidores de la interaccion proteina-proteina de mll1-wdr5 de cruce de la barrera hematoencefalica y usos de estos MX2024011346A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263319589P 2022-03-14 2022-03-14
PCT/US2023/015021 WO2023177592A1 (en) 2022-03-14 2023-03-10 Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2024011346A true MX2024011346A (es) 2025-01-09

Family

ID=88024124

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011346A MX2024011346A (es) 2022-03-14 2024-09-13 Compuestos inhibidores de la interaccion proteina-proteina de mll1-wdr5 de cruce de la barrera hematoencefalica y usos de estos

Country Status (7)

Country Link
US (1) US20230293539A1 (cg-RX-API-DMAC7.html)
EP (1) EP4493184A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509830A (cg-RX-API-DMAC7.html)
KR (1) KR20250009417A (cg-RX-API-DMAC7.html)
CA (1) CA3245866A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024011346A (cg-RX-API-DMAC7.html)
WO (1) WO2023177592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250134899A1 (en) * 2023-10-27 2025-05-01 Huyabio International, Llc Combination therapies of wdr5 inhibitors and pd-1 inhibitors
TW202619730A (zh) 2024-09-13 2026-05-16 日商亞力維克希斯股份有限公司 Wdr5抑制劑、化合物、醫藥組合物、及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063058B2 (en) * 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US11319299B2 (en) * 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
CN107382840B (zh) * 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
JP2020532561A (ja) * 2017-09-06 2020-11-12 プロペロン セラピューティクス インコーポレイテッド Wdr5タンパク質−タンパク質結合の阻害剤
CN108715585A (zh) * 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
HRP20240293T1 (hr) * 2018-09-18 2024-05-24 F. Hoffmann - La Roche Ag Derivati kinazolina kao protutumorska sredstva
CN109734674B (zh) * 2019-02-26 2022-08-26 中国药科大学 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
TWI899080B (zh) * 2019-05-27 2025-10-01 大陸商迪哲(江蘇)醫藥股份有限公司 Dna依賴性蛋白激酶抑制劑

Also Published As

Publication number Publication date
EP4493184A1 (en) 2025-01-22
WO2023177592A1 (en) 2023-09-21
KR20250009417A (ko) 2025-01-17
CA3245866A1 (en) 2023-09-21
US20230293539A1 (en) 2023-09-21
EP4493184A4 (en) 2026-03-18
JP2025509830A (ja) 2025-04-11

Similar Documents

Publication Publication Date Title
WO2022221528A3 (en) Kras g12c inhibitors
MX2025003398A (es) Nuevo compuesto tetraheterociclico
PH12022552410A1 (en) Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
EP4477220A3 (en) Plasma kallikrein inhibitors and uses thereof
ZA202208783B (en) Kras mutant protein inhibitors
MX2024003922A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos.
MX2021002640A (es) Formas morficas de los inhibidores del factor d del complemento.
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
ECSP045126A (es) INHIBIDORES DEL FACTOR Xa Y DE OTRAS PROTEASAS DE SERINA IMPLICADAS EN LA CASCADA DE LA COAGULACIÓN
WO2003065987A3 (en) Granzyme b inhibitors
MX2025008920A (es) Inhibidores de parp1 triciclicos y usos de estos
MX2023011014A (es) Inhibidores de heteroarílo de la calicreína plasmática.
MX2021003425A (es) Formas morficas de los inhibidores del factor d del complemento.
CR10636A (es) Inhibidor de quinasa
JOP20220290A1 (ar) مثبطات إنزيم الجلوكوسيل سيراميداز غير المتعلقة بالجسيم الحال واستخدامتها
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
MX2025003571A (es) Inhibidores de tead y metodos de uso de los mismos
MX2024011348A (es) Inhibidor de la interacción proteína-proteína mll1-wdr5 de feniltriazol.
JOP20230091A1 (ar) مثبط magl
JOP20220291A1 (ar) مثبطات جلوكوزيل سيراميدز غير متعلقة بالجسم الحال واستخداماتها
MX2025003568A (es) Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap)
MX2023007992A (es) Compuestos cuadracíclicos fundidos, composiciones y usos de los mismos.
DE60329326D1 (de) Tace inhibitoren